1. A wireless communication terminal, comprising:
an output unit for outputting an alert signal;
a storage for storing multimedia data and valid playing time of the multimedia data; and
a main processor for controlling the output unit to output the alert signal by checking a valid playing time of the multimedia data stored in the storage.
2. The wireless communication terminal as recited in claim 1, wherein the storage further includes multimedia data information;
the main processor further performs a control to display at least one of the multimedia data information, the valid playing time, and a remaining time; and
the wireless communication terminal further includes a display unit for displaying the multimedia data information, the valid playing time, and the remaining time under control of the main processor.
3. The wireless communication terminal as recited in claim 2, wherein the multimedia data information includes at least one of a file name, a title of the multimedia data, and a name of a singer.
4. The wireless communication terminal as recited in claim 2, wherein the main processor checks up the valid playing time of the multimedia data stored in the storage periodically and controls the components to output an alert signal when the remaining time of the valid playing time of the multimedia data is in a range of an alert time.
5. The wireless communication terminal as recited in claim 1, wherein the storage further includes multimedia data information;
the main processor further controls the storage and the output unit to output the multimedia data information, the valid playing time, and the remaining time; and
the output unit outputs the multimedia data information, the valid playing time, and the remaining time in a form of speech under the control of the main processor.
6. The wireless communication terminal as recited in claim 5, wherein the main processor checks up the valid playing time of the multimedia data stored in the storage periodically and controls the components to output an alert signal when the remaining time of the valid playing time of the multimedia data is in a range of an alert time.
7. The wireless communication terminal as recited in claim 1, wherein the main processor controls the output unit to output the multimedia data information, the valid playing time, and the remaining time along with an alert signal by checking the valid playing time of the multimedia data stored in the storage.
8. The wireless communication terminal as recited in claim 7, wherein the main processor checks up the valid playing time of the multimedia data stored in the storage periodically and controls the components to output an alert signal when the remaining time of the valid playing time of the multimedia data is in a range of an alert time.
9. A wireless communication terminal, comprising:
an input unit for receiving multimedia data executing signals;
a storage for storing multimedia data, multimedia data information, an entire playing time, and valid playing time of the multimedia data;
a main processor for checking the valid playing time of the multimedia data stored in the storage upon receipt of a sound requesting to execute the multimedia data through the input unit, comparing the valid playing time of the multimedia data with the entire playing time, and outputting an alert informing that the execution of the multimedia data is rejected, executing the multimedia data while displaying the remaining time of the multimedia data, or executing the multimedia data according to the comparison result;
a display unit for displaying the remaining time of the multimedia data or an alert informing that the execution of the multimedia data is rejected under the control of the main processor; and
an output unit for outputting multimedia data signals executed under the control of the main processor.
10. The wireless communication terminal as recited in claim 9, wherein the main processor controls the display unit to display the valid playing time of the multimedia data along with the remaining time.
11. A method for informing a valid playing time of multimedia data in a wireless communication terminal, comprising the steps of:
a) storing multimedia data and valid playing time of the multimedia data;
b) checking the valid playing time of the multimedia data periodically; and
c) outputting an alert signal if a remaining time of the valid playing time of the multimedia data is in a range of an alert time.
12. The method as recited in claim 11, wherein multimedia data information is further stored in the step a); and
at least one of the multimedia data information the valid playing time, and the remaining time are outputted together with the alert signal outputted in the step c).
13. The method as recited in claim 12, wherein the alert time range is established in the main processor of the wireless communication terminal according to a selection of a user.
14. The method as recited in claim 11, wherein at least one of the multimedia data information, the valid playing time and the remaining time are outputted along with the alert signal in the step c)
15. A method for informing a valid playing time in a wireless communication terminal, comprising the steps of:
a) storing multimedia data and valid playing time of the multimedia data;
b) receiving a signal for executing the multimedia data;
c) determining whether the valid playing time of the multimedia data is expired;
d) outputting an alert informing that the execution of the multimedia data is rejected, if the valid playing time of the multimedia data is expired;
e) comparing a remaining time of the valid playing time of the multimedia data with the entire playing time of the multimedia data, if the valid playing time of the multimedia data is not expired;
f) if the remaining time of the multimedia data is shorter than the entire playing time of the multimedia data, displaying the remaining time of the multimedia data and executing the multimedia data; and
g) if the remaining time of the multimedia data is longer than the entire playing time of the multimedia data, executing the multimedia data.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of treating urogenital-neurological disorder in a mammal, the method comprising the step of administering to the mammal in need thereof a therapeutically effective amount of a composition including a TVEMP comprising a retargeted peptide binding domain, a Clostridial toxin translocation domain and a Clostridial toxin enzymatic domain,
wherein the retargeted peptide binding domain is a tachykinin peptide binding domain, a Neuropeptide Y related peptide binding domain, or a kinin peptide binding domain, and
wherein administration of the composition reduces a symptom of the urogenital-neurological disorder, thereby treating the mammal.
2. The method of claim 1, wherein the TVEMP comprises a linear amino-to-carboxyl single polypeptide order of 1) the Clostridial toxin enzymatic domain, the Clostridial toxin translocation domain, the retargeted peptide binding domain, 2) the Clostridial toxin enzymatic domain, the retargeted peptide binding domain, the Clostridial toxin translocation domain, 3) the retargeted peptide binding domain, the Clostridial toxin translocation domain, and the Clostridial toxin enzymatic domain, 4) the retargeted peptide binding domain, the Clostridial toxin enzymatic domain, the Clostridial toxin translocation domain, 5) the Clostridial toxin translocation domain, the Clostridial toxin enzymatic domain and the retargeted peptide binding domain, or 6) the Clostridial toxin translocation domain, the retargeted peptide binding domain and the Clostridial toxin enzymatic domain.
3. The method of claim 1, wherein the Clostridial toxin translocation domain is a BoNTA translocation domain, a BoNTB translocation domain, a BoNTC1 translocation domain, a BoNTD translocation domain, a BoNTE translocation domain, a BoNTF translocation domain, a BoNTG translocation domain, a TeNT translocation domain, a BaNT translocation domain, or a BuNT translocation domain.
4. The method of claim 1, wherein the Clostridial toxin enzymatic domain is a BoNTA enzymatic domain, a BoNTB enzymatic domain, a BoNTC1 enzymatic domain, a BoNTD enzymatic domain, a BoNTE enzymatic domain, a BoNTF enzymatic domain, a BoNTG enzymatic domain, a TeNT enzymatic domain, a BaNT enzymatic domain, or a BuNT enzymatic domain.
5. The method of claim 1, wherein the urogenital-neurological disorder is urinary incontinence, overactive bladder, detrusor dysfunction, lower urinary tract dysfunction, urinary retention, urinary hesitancy, polyuria, nocturia, chronic urinary tract infection, an urogenital disorder associated with a prostate disorder, an urogenital disorder associated with a uterine disorder, or an urogenital disorder associated with a neurogenic dysfunction.
6. A method of treating urogenital-neurological disorder in a mammal, the method comprising the step of administering to the mammal in need thereof a therapeutically effective amount of a composition including a TVEMP comprising a retargeted peptide binding domain, a Clostridial toxin translocation domain, a Clostridial toxin enzymatic domain, and an exogenous protease cleavage site, wherein the retargeted peptide binding domain is a tachykinin peptide binding domain, a Neuropeptide Y related peptide binding domain, or a kinin peptide binding domain, and wherein administration of the composition reduces a symptom of the urogenital-neurological disorder, thereby treating the mammal.
7. The method of claim 6, wherein the TVEMP comprises a linear amino-to-carboxyl single polypeptide order of 1) the Clostridial toxin enzymatic domain, the exogenous protease cleavage site, the Clostridial toxin translocation domain, the retargeted peptide binding domain, 2) the Clostridial toxin enzymatic domain, the exogenous protease cleavage site, the retargeted peptide binding domain, the Clostridial toxin translocation domain, 3) the retargeted peptide binding domain, the Clostridial toxin translocation domain, the exogenous protease cleavage site and the Clostridial toxin enzymatic domain, 4) the retargeted peptide binding domain, the Clostridial toxin enzymatic domain, the exogenous protease cleavage site, the Clostridial toxin translocation domain, 5) the Clostridial toxin translocation domain, the exogenous protease cleavage site, the Clostridial toxin enzymatic domain and the retargeted peptide binding domain, or 6) the Clostridial toxin translocation domain, the exogenous protease cleavage site, the retargeted peptide binding domain and the Clostridial toxin enzymatic domain.
8. The method of claim 6, wherein the Clostridial toxin translocation domain is a BoNTA translocation domain, a BoNTB translocation domain, a BoNTC1 translocation domain, a BoNTD translocation domain, a BoNTE translocation domain, a BoNTF translocation domain, a BoNTG translocation domain, a TeNT translocation domain, a BaNT translocation domain, or a BuNT translocation domain.
9. The method of claim 6, wherein the Clostridial toxin enzymatic domain is a BoNTA enzymatic domain, a BoNTB enzymatic domain, a BoNTC1 enzymatic domain, a BoNTD enzymatic domain, a BoNTE enzymatic domain, a BoNTF enzymatic domain, a BoNTG enzymatic domain, a TeNT enzymatic domain, a BaNT enzymatic domain, or a BuNT enzymatic domain.
10. The method of claim 6, wherein the exogenous protease cleavage site is a plant papain cleavage site, an insect papain cleavage site, a crustacian papain cleavage site, an enterokinase cleavage site, a human rhinovirus 3C protease cleavage site, a human enterovirus 3C protease cleavage site, a tobacco etch virus protease cleavage site, a Tobacco Vein Mottling Virus cleavage site, a subtilisin cleavage site, a hydroxylamine cleavage site, or a Caspase 3 cleavage site.
11. The method of claim 6, wherein the urogenital-neurological disorder is urinary incontinence, overactive bladder, detrusor dysfunction, lower urinary tract dysfunction, urinary retention, urinary hesitancy, polyuria, nocturia, chronic urinary tract infection, an urogenital disorder associated with a prostate disorder, an urogenital disorder associated with a uterine disorder, or an urogenital disorder associated with a neurogenic dysfunction.
12. Use of a TVEMP in the manufacturing a medicament for treating urogenital-neurological disorder in a mammal in need thereof, wherein the TVEMP comprising a retargeted peptide binding domain, a Clostridial toxin translocation domain and a Clostridial toxin enzymatic domain, wherein the retargeted peptide binding domain is a tachykinin peptide binding domain, a Neuropeptide Y related peptide binding domain, or a kinin peptide binding domain, and wherein administration of a therapeutically effective amount of the medicament to the mammal reduces a symptom of the urogenital-neurological disorder, thereby treating the mammal.
13. A use of a TVEMP in the manufacturing a medicament for treating urogenital-neurological disorder in a mammal in need thereof, the use comprising the step of administering to the mammal a therapeutically effective amount of the composition, wherein the TVEMP comprising a retargeted peptide binding domain, a Clostridial toxin translocation domain, a Clostridial toxin enzymatic domain, and an exogenous protease cleavage site, wherein the retargeted peptide binding domain is a tachykinin peptide binding domain, a Neuropeptide Y related peptide binding domain, or a kinin peptide binding domain, and wherein administration of the composition reduces a symptom of the urogenital-neurological disorder, thereby treating the mammal.